Hematocrit: What Your Result Means and Which Drugs Distort It

What Hematocrit Actually Measures

Hematocrit is the fraction of your whole blood volume made up by red blood cells, expressed as a percentage. Run it correctly and it tells your clinician whether you are carrying enough oxygen or whether your blood is suspiciously thick.

The test itself is simple. A sample of your blood is spun in a centrifuge; the red cells pack to the bottom, and the ratio of that packed column to the total column length is your hematocrit. It is one of the most replicated measurements in clinical medicine, reported as part of the complete blood count (CBC) alongside hemoglobin and red-cell indices.

Why the Reference Range Is Different for Women

Sex hormones drive red-cell production. Testosterone stimulates erythropoietin release in the kidneys, which tells bone marrow to make more red cells. Because women have lower circulating testosterone, they produce fewer red blood cells on average, and their hematocrit sits about 3 to 5 percentage points below men's across the adult lifespan.

Monthly menstrual blood loss also contributes. Women who menstruate regularly lose iron and red-cell mass each cycle, which keeps the hematocrit at the lower end of the female reference range. The CDC defines iron-deficiency anemia as hemoglobin <12 g/dL in non-pregnant women, a threshold that corresponds to hematocrit values typically below 36 percent.

How Your Life Stage Shifts the "Normal" Band

The reference range is not a fixed number. It moves with your reproductive status:

• Reproductive years (with regular periods): Baseline 36 to 46 percent. Heavy menstrual bleeding (HMB) can pull it below 36 percent chronically.
• Trying to conceive / early pregnancy: Values begin dropping within the first trimester as plasma volume expands faster than red-cell mass.
• Third trimester: Physiologic dilutional anemia is expected. A hematocrit of 33 percent or above is considered acceptable by ACOG.
• Postpartum: Hematocrit typically recovers by six weeks, but postpartum hemorrhage or inadequate iron intake can slow that recovery.
• Perimenopause: Cycles become irregular and eventually stop. The monthly iron and red-cell drain disappears, so hematocrit may drift upward by 1 to 3 percentage points compared to your reproductive-year baseline.
• Postmenopause: Without monthly losses and with possible hormonal therapy changes, the hematocrit often settles at the higher end of the female range or slightly above it.

Low Hematocrit in Women: Common Causes Beyond Anemia

A hematocrit below 36 percent in a non-pregnant woman, or below 33 percent in the third trimester, signals that red-cell mass, iron supply, or both are inadequate.

Iron-Deficiency Anemia From Heavy Menstrual Bleeding

This is the single most common cause of low hematocrit in women of reproductive age. Approximately 10 million women in the United States have iron-deficiency anemia, and heavy menstrual bleeding accounts for the majority of cases in the premenopausal group. Fibroids, endometriosis, and adenomyosis all worsen menstrual losses and drive the hematocrit down.

Vitamin B12 and Folate Deficiency

These cause a different picture. Red cells become large and misshapen (macrocytic anemia). Hematocrit drops even though the marrow is trying hard to compensate. Women who follow a strict vegan diet, women who have had bariatric surgery, and women taking metformin long-term are at elevated risk for B12 depletion. Metformin reduces B12 absorption by about 30 percent in long-term users according to data published in the Archives of Internal Medicine and confirmed in the TMIC cohort.

Chronic Disease and Kidney Disease

Chronic kidney disease impairs erythropoietin production. Women with diabetic nephropathy, lupus nephritis, or long-standing hypertensive kidney damage can develop anemia of chronic kidney disease, with hematocrit chronically in the 28 to 35 percent range.

High Hematocrit in Women: When to Worry

A hematocrit above 48 percent in a woman warrants investigation. Mild elevation can reflect dehydration, but persistent elevation points to a real increase in red-cell mass.

Polycythemia Vera

This myeloproliferative neoplasm drives overproduction of red cells independent of erythropoietin. Women with polycythemia vera face a real risk of thrombosis, particularly deep vein thrombosis and stroke. The diagnosis requires a JAK2 mutation test alongside the hematocrit finding.

High-Altitude Living

At elevations above 2,500 meters, lower oxygen tension stimulates erythropoietin, and hematocrit climbs. This is a physiologic adaptation, not a disease, but it can confuse interpretation if your clinician does not know your altitude.

Testosterone Therapy and Hematocrit: The Most Clinically Urgent Drug Effect

This deserves its own extended section because it is the drug-hematocrit interaction most likely to affect women using WomanRx.

Drugs That Raise Hematocrit

Certain medications directly stimulate red-cell production or concentrate the blood, pushing your hematocrit above the normal female range.

Testosterone (Exogenous Androgens)

This is the most clinically significant drug that raises hematocrit in women.

Testosterone at any dose stimulates erythropoietin release. The effect is dose-dependent and cumulative. In men receiving testosterone replacement therapy (TRT), polycythemia (hematocrit >52%) develops in roughly 7 to 14 percent of patients. The data in women is thinner, because women were largely excluded from the landmark androgen trials, but the mechanism is identical.

Women encounter exogenous testosterone in several settings:

• HSDD treatment: The ISSWSH and SMSNA position statement on testosterone for HSDD in women recommends the lowest effective dose (targeting a serum testosterone at or near the upper limit of the normal female range, approximately 40 to 70 ng/dL). Even at these physiologic female doses, hematocrit should be checked at baseline and at 3 to 6 months.
• Gender-affirming hormone therapy (GAHT): Transmasculine individuals using testosterone in masculinizing doses see hematocrit rise into the male reference range and occasionally above it. The Endocrine Society Clinical Practice Guideline on gender dysphoria recommends monitoring hematocrit every 3 months in the first year of GAHT.
• DHEA supplementation: Over-the-counter DHEA converts to androstenedione and then testosterone in peripheral tissues. Doses above 25 mg/day may raise hematocrit modestly, particularly in postmenopausal women with higher peripheral aromatase activity.

The WomanRx Hematocrit Monitoring Framework for Women on Testosterone:

| Life Stage | Testosterone Context | Monitoring Interval | |---|---|---| | Reproductive years (HSDD dose) | <25 mg/week topical | Baseline, 3 months, then annually | | Perimenopause (HSDD dose) | <25 mg/week topical | Baseline, 3 months, then annually | | Postmenopause (HSDD dose) | <25 mg/week topical | Baseline, 3 months, then 6-monthly | | Transmasculine GAHT | Masculinizing dose | Every 3 months in year 1, then every 6 months | | PCOS with supraphysiologic androgens | Endogenous, no drug needed | Check hematocrit if hgb >13 |

The Endocrine Society guideline on testosterone therapy sets the polycythemia action threshold at hematocrit >54 percent. At that level, the standard recommendation is to withhold testosterone until the hematocrit falls below 50 percent, then restart at a lower dose or a longer dosing interval.

Erythropoiesis-Stimulating Agents (ESAs)

Drugs such as epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) are prescribed for anemia of chronic kidney disease and chemotherapy-induced anemia. They directly stimulate the bone marrow to produce more red cells. Hematocrit rises predictably, and the FDA mandated updated safety labeling in 2011 warning against targeting hemoglobin above 11 g/dL (roughly hematocrit >33 percent) in CKD patients because higher targets increased cardiovascular risk in the TREAT trial.

Diuretics and Dehydration-Associated Medications

Loop diuretics (furosemide), thiazides (hydrochlorothiazide, chlorthalidone), and osmotic agents shrink plasma volume without reducing red-cell mass. The hematocrit rises because the denominator shrinks, not because you have more red cells. This is a spurious elevation. Rehydration corrects it within hours. Women taking diuretics for heart failure or hypertension should always have their CBC drawn before, not during or immediately after, a diuretic dose, and ideally in a euvolemic state.

Corticosteroids

High-dose oral corticosteroids such as prednisone (doses of 20 mg/day or above for more than two weeks) can modestly raise hematocrit through two mechanisms: mild stimulation of erythropoiesis and mild plasma-volume contraction. The effect is usually small (1 to 3 percentage points) and reverses with dose reduction.

Androgens Used in Other Contexts

Danazol, a synthetic androgen used historically for endometriosis and hereditary angioedema, raises hematocrit at therapeutic doses. Its use has declined sharply with the arrival of GnRH agonists and newer endometriosis treatments, but it remains in use for some hereditary angioedema cases. If you are taking danazol, your CBC should be monitored every 3 to 6 months.

Drugs That Lower Hematocrit

Chemotherapy and Myelosuppressive Agents

Cytotoxic chemotherapy suppresses bone marrow broadly. Nearly all platinum-based regimens, anthracyclines, and taxanes cause anemia to some degree. Approximately 40 percent of patients receiving chemotherapy develop clinically significant anemia (hemoglobin <10 g/dL, hematocrit <30%). For women with breast, ovarian, cervical, or endometrial cancer, this is a treatment-limiting toxicity that affects quality of life and sometimes dose intensity.

Hydroxyurea

Hydroxyurea is used for sickle cell disease and certain myeloproliferative disorders. It intentionally suppresses red-cell production as part of its mechanism. Hematocrit suppression is expected and monitored closely. In women with sickle cell disease who are trying to conceive, hydroxyurea is classified as teratogenic by ACOG and must be discontinued before conception attempts (see the Pregnancy and Lactation section below).

Metformin

As noted above, long-term metformin use reduces B12 absorption. Sustained B12 depletion eventually causes macrocytic anemia with a falling hematocrit. The effect takes months to years to manifest and is easily missed unless B12 is checked alongside the CBC. Women with PCOS who are on metformin long-term should have B12 measured at least annually; the American Diabetes Association Standards of Care recommend periodic B12 testing for all patients on long-term metformin.

ACE Inhibitors and Angiotensin Receptor Blockers

ACE inhibitors (lisinopril, enalapril) and ARBs (losartan, valsartan) modestly suppress erythropoiesis by reducing angiotensin II, which normally stimulates erythropoietin. In women post-kidney transplant, this effect is used therapeutically to manage post-transplant erythrocytosis. In the general population, the drop in hematocrit is mild (1 to 2 percentage points) and rarely causes symptoms.

Ribavirin (Hepatitis C)

Ribavirin causes hemolytic anemia through oxidative damage to red-cell membranes. Hematocrit can fall 4 to 5 percentage points within the first four weeks of therapy. With direct-acting antivirals now replacing ribavirin-based regimens for hepatitis C, this effect is less common but still relevant for women on older combination protocols or who are being re-treated.

Antiretroviral Agents (Zidovudine / AZT)

Zidovudine suppresses bone marrow directly. Macrocytic anemia occurs in up to 30 percent of patients on zidovudine-containing regimens, and hematocrit can drop sharply in the first 4 to 6 weeks. Women living with HIV, including those who are pregnant and being managed with older protocols, need CBC monitoring every 4 weeks during the first 3 months of zidovudine-containing treatment per NIH guidelines on antiretrovirals in pregnancy.

NSAIDs and GI Blood Loss

Chronic NSAID use (ibuprofen, naproxen, high-dose aspirin) causes occult gastrointestinal blood loss in a meaningful proportion of users. Over months, this iron loss is indistinguishable from heavy-period-related iron deficiency on a CBC. Women who take NSAIDs regularly for dysmenorrhea, endometriosis pain, or chronic pain should have their hematocrit and ferritin checked at least annually.

Antiepileptic Drugs

Valproic acid, carbamazepine, and phenytoin are associated with macrocytic anemia through folate interference or direct marrow suppression. Women with epilepsy who are of reproductive age often have complex interactions here, because these drugs are also teratogens, meaning that the hematocrit finding arrives in a broader conversation about contraception and preconception planning.

Pregnancy and Lactation: Special Interpretation Rules

This section applies to every drug discussed above. Read it before starting, continuing, or stopping any medication while pregnant or breastfeeding.

Physiologic Dilution Changes the Reference Range

During pregnancy, plasma volume expands by approximately 45 to 50 percent while red-cell mass expands by only 20 to 30 percent. This dilutional anemia is normal and expected. ACOG defines anemia in pregnancy as hemoglobin <11 g/dL in the first and third trimesters, and <10.5 g/dL in the second trimester, corresponding to hematocrit values roughly below 33 to 34 percent.

Drug-by-Drug Pregnancy and Lactation Flags

Testosterone: Contraindicated in pregnancy. Exogenous androgens cause virilization of female fetuses and are associated with genital ambiguity. Any woman of reproductive age using testosterone for HSDD must use reliable contraception. If pregnancy is suspected, stop testosterone immediately and contact your clinician.

Hydroxyurea: Teratogenic. ACOG recommends discontinuation at least 3 months before attempted conception. Breastfeeding is contraindicated because hydroxyurea transfers into breast milk.

ESAs (epoetin alfa, darbepoetin alfa): Limited human data in pregnancy. Use only if benefit clearly outweighs risk. Epoetin alfa does not appear to cross the placenta in significant amounts, but safety data from prospective trials in pregnant women is sparse. Clinicians generally continue ESAs for CKD-related anemia in pregnancy when hemoglobin falls below 10 g/dL, consistent with ACOG guidance on renal disease in pregnancy.

Metformin: Considered compatible with pregnancy for gestational diabetes and PCOS-related ovulation induction. B12 monitoring becomes more important in pregnant women on metformin, because B12 deficiency in pregnancy carries its own fetal neural tube risks.

NSAIDs: Avoid after 20 weeks of gestation. The FDA updated labeling in 2020 to warn that NSAID use after 20 weeks may cause fetal renal dysfunction and oligohydramnios. Before 20 weeks, short-term use for pain is generally considered low risk.

Ribavirin: Pregnancy category X. Ribavirin is highly teratogenic. Women and female partners of men taking ribavirin must use two forms of contraception during treatment and for 6 months after stopping, per FDA labeling.

Valproic acid: Pregnancy category D/X. Major teratogen (neural tube defects, cognitive effects). Women of reproductive age on valproic acid require documented contraception counseling and should be offered high-dose folic acid (5 mg/day) if pregnancy occurs. The hematocrit finding may prompt your clinician to address this broader picture.

Zidovudine: Used in pregnancy for prevention of perinatal HIV transmission. CBC monitoring is more frequent in pregnant women on zidovudine because the marrow suppression occurs against a background of physiologic anemia. NIH recommends CBC checks every 4 weeks in the first trimester when zidovudine is used.

Who Should Have Their Hematocrit Checked More Frequently

Standard preventive care includes a CBC as part of a general health screen, but certain women need more frequent monitoring:

Women at Elevated Risk for Low Hematocrit

• Heavy menstrual bleeding (greater than 80 mL per cycle, or periods lasting more than 7 days)
• Fibroids or adenomyosis
• Vegetarian or vegan diet
• Bariatric surgery (especially Roux-en-Y gastric bypass)
• Long-term metformin use (>1 year)
• Chronic NSAID use
• Active cancer treatment
• HIV on zidovudine-containing regimen
• Celiac disease or inflammatory bowel disease with malabsorption

Women at Elevated Risk for High Hematocrit

• Testosterone therapy at any dose (HSDD, GAHT)
• Danazol therapy
• Known JAK2 mutation or polycythemia vera
• Residence above 2,500 meters altitude
• Active or prior smoking (carbon monoxide shifts the oxygen-dissociation curve and stimulates compensatory erythropoiesis)
• Chronic obstructive pulmonary disease or sleep apnea (both cause nocturnal hypoxia)

How to Lower a High Hematocrit (and When Drugs Are the Cause)

If your hematocrit is above 48 percent and you are a woman, your clinician's first step is usually to identify the cause before treating the number.

If the cause is testosterone: The Endocrine Society recommends stopping testosterone if hematocrit exceeds 54 percent, then restarting at a lower dose once it returns below 50 percent. In some cases, therapeutic phlebotomy (removal of a unit of blood) is used to bring the hematocrit down quickly.

If the cause is dehydration: Oral rehydration over 24 to 48 hours typically normalizes a dilution-driven elevation. No further treatment is needed.

If the cause is polycythemia vera: Treatment options include phlebotomy, low-dose aspirin, and cytoreductive therapy such as hydroxyurea or pegylated interferon alfa. Management is coordinated with hematology.

If the cause is sleep apnea: Treating the apnea with CPAP reduces the hypoxic stimulus for erythropoiesis. Hematocrit typically falls over 3 to 6 months of consistent CPAP use.

How to Raise a Low Hematocrit (Targeted, Not Generic)

"Take iron" is not a complete answer. Treatment depends on the underlying cause.

Iron-deficiency anemia from HMB: Oral iron (ferrous sulfate 325 mg once or twice daily, taken with vitamin C) is first-line. If oral iron fails due to GI intolerance or ongoing losses, intravenous iron (ferric carboxymaltose, 750 to 1,000 mg as a single infusion) replenishes stores faster. Treating the underlying HMB with hormonal therapy (combined oral contraceptives, progestins, or a levonorgestrel-releasing IUD) addresses the source.

B12 deficiency: Oral B12 1,000 mcg daily is effective even for pernicious anemia in most patients. Evidence from a Cochrane review shows oral high-dose B12 achieves equivalent serum levels to intramuscular injection in most patients.

Chemotherapy-induced anemia: ESAs are an option when hemoglobin drops below 10 g/dL, but ASCO guidelines recommend using the lowest effective dose to avoid increasing cardiovascular and thromboembolic risk. Iron supplementation alongside ESAs improves response rates.

Questions Women Ask About Hematocrit